This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.
Kadcyla (Ado-Trastuzumab Emtansine) injection is an antibody-drug conjugate engineered to deliver potent chemotherapy directly to HER2-positive cancer cells, potentially limiting damage to healthy tissues. It combines two anti-cancer properties joined together by a stable linker: the HER2-targeting properties of trastuzumab (the active ingredient in Herceptin) and the chemotherapy agent DM1.
It is indicated for HER2-positive metastatic breast cancer (MBC), and as adjuvant treatment (after primary treatment) of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease.
If a patient becomes pregnant while receiving KADCYLA, or within 7 months following the last dose of Kadcyla, please immediately report pregnancy to the local Roche Adverse Event Line at
In case of any adverse events or safety queries, please contact:
If you have a scientific query related to one of Roche's products, please contact:
M-PK-00001707
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.
Please be aware that you are leaving this website.